Unknown

Dataset Information

0

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?

ABSTRACT:

SUBMITTER: Harbeck N 

PROVIDER: S-EPMC6048618 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?

Harbeck Nadia N  

Therapeutic advances in medical oncology 20180711

Similar Datasets

Unknown Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy.
| S-EPMC9851067 | biostudies-literature
Unknown Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy.
| S-EPMC10104267 | biostudies-literature
Unknown Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
| S-EPMC10795510 | biostudies-literature
Unknown Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies.
| S-EPMC11937365 | biostudies-literature
Unknown Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
| S-EPMC8172481 | biostudies-literature
Unknown The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status.
| S-EPMC8165305 | biostudies-literature
Unknown Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.
| S-EPMC11799161 | biostudies-literature
Unknown Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.
| S-EPMC6314865 | biostudies-literature
Unknown Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
| S-EPMC11261254 | biostudies-literature
Unknown Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
| S-EPMC8508505 | biostudies-literature